Respiratory syncytial virus (RSV)
RSV is a seasonal virus that primarily affects children under 5 and adults over 60. Infants born prematurely face a greater risk of contracting RSV and are more likely to need hospitalization compared with those born at full term, because their respiratory system is not yet fully developed. Other at-risk populations include infants with chronic lung conditions and infants with hemodynamically significant congenital heart disease (HS-CHD). Each year in the United States, RSV causes about 58,000 to 80,000 hospitalizations in children under 5 and 100,000 to 150,000 in adults over 60.
RSV publications
The publications on this page are sponsored by Sobi and pertain to select Sobi products in this disease area. This page is not intended to serve as a comprehensive overview of all publications in this disease area. Publications may include information for which the product is not approved and/or that is inconsistent with the product uses described in the Prescribing Information. Sobi does not suggest or recommend the use of Sobi products in any manner other than as described in the Prescribing Information.
Connect with an MSL
Sobi Medical Science Liaisons are highly trained, scientific and clinical subject matter experts who can provide in-depth answers to your disease and treatment questions.